Neurokey is a Europe-based biotech company that develops first-in-class drugs for the critical care segment. It was founded in 2007.
Neurokey addresses a pressing market need for emergency medication that can increase survival rate and reduce the risk of lasting neurological damage in critical care patients.
The four founders of Neurokey all have extensive knowledge of critical care, which they have gained from years of first-hand experience as practising doctors. Their in-depth understanding of physicians’ needs in the segment is the cornerstone of Neurokey product development.
Neurokey is located in the centre of Medicon Valley, one of the biggest biotechnological and pharmaceutical clusters in Europe.
Neurokey wants to become a leading drug development company in the critical care field.
The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological diseases. Neurokey will be first-to-market with reliable, efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimise the risk of permanent neurological damage.
Neurokey is building a portfolio of drugs under development for the critical care segment. Neurokey products are based on both original ideas and in-licensing from other companies, institutions and universities.
Neurokey drug candidates are innovative, first-in-class products. Neurokey R&D is committed to going further than simply creating incremental improvements on existing marketed drugs.
Pushing the boundaries of existing research creates a dynamic that can better lead to technological and market breakthroughs. Ultimately, this will ensure that future patients get the best possible treatment for their critical condition.
Neurokey already has an impressive IPR platform protecting its core development projects. Neurokey will continue to broaden its IPR portfolio in accordance with overall company IP strategy.
Malene Weis comes from a position as Director of Clinical Development in Osteologix and has worked in biotech and pharmaceutical companies for more than 15 years. As Director of Clinical Operations, she will be a significant driver of the process towards the upcoming clinical trials.
Keld Fosgerau leaves a position as Manager, Senior Research Scientist at Rheoscience to join Neurokey. His more than 10 years of industry experience within drug discovery and pharmacology research, preceded by a PhD, constitutes a significant strengthening of Neurokey’s project management and preclinical development capabilities.
We are happy to announce the appointment of Charlotte Videbaek as new CEO of Neurokey as of August 1st 2008. Charlotte Videbaek brings two decades of neurological expertise: 12 years in academia (MD, DMSc, Specialist in Neurology) and 8 years in the pharma industry (Novartis Pharma AG and Hoffmann-La Roche). She leaves her position as Head of Department for International Clinical Research in Neurology at H. Lundbeck to join Neurokey.
The attraction of a CEO of Charlotte Videbaek’s caliber is a milestone in Neurokey’s growth and, with the additition of her significant expertise in clinical development, it embodies the company’s transformation into a clinical development company.
Charlotte Videbaek succeeds Jacob Gotfredsen who as co-founder and CEO through the initial start-up fase and series A fund-raising has been instrumental in Neurokey’s current success. Jacob Gotfredsen continues as part of the executive management as Chief Business Officer.
You can contact me via us to info@neurokey.com, or reach us at the following address: